Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BRAF D594G

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

BRAF D594G	Non Small Cell Lung Cancer	BRAF D594G	Non Small Cell Lung Cancer	trametinib Resistant: C3 – Early Trials trametinib Resistant : C3	trametinib Resistant: C3 – Early Trials trametinib Resistant : C3
BRAF D594G	Non Small Cell Lung Cancer	BRAF D594G	Non Small Cell Lung Cancer	trametinib + dabrafenib Resistant: C3 – Early Trials trametinib + dabrafenib Resistant : C3	trametinib + dabrafenib Resistant: C3 – Early Trials trametinib + dabrafenib Resistant : C3
BRAF D594G	Ampulla of Vater Carcinoma	BRAF D594G	Ampulla of Vater Carcinoma	binimetinib + encorafenib Sensitive: C3 – Early Trials binimetinib + encorafenib Sensitive : C3	binimetinib + encorafenib Sensitive: C3 – Early Trials binimetinib + encorafenib Sensitive : C3
BRAF D594G	Melanoma	BRAF D594G	Melanoma	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
BRAF D594G	Colorectal Cancer	BRAF D594G	Colorectal Cancer	cetuximab + encorafenib + BVD-523 Sensitive: C3 – Early Trials cetuximab + encorafenib + BVD-523 Sensitive : C3	cetuximab + encorafenib + BVD-523 Sensitive: C3 – Early Trials cetuximab + encorafenib + BVD-523 Sensitive : C3
BRAF D594G	Cholangiocarcinoma	BRAF D594G	Cholangiocarcinoma	trametinib Sensitive: C4 – Case Studies trametinib Sensitive : C4	trametinib Sensitive: C4 – Case Studies trametinib Sensitive : C4